Nicolas CS and Navarro C
Virbac, France
Posters & Accepted Abstracts: J Vet Sci Technol
Metronidazole is indicated in veterinary medicine to treat gastro-intestinal diseases caused by Giardia spp. or by
anaerobic bacteria, such as Clostridium spp. The pharmaceutical form and acceptability is of great importance
to allow good treatment compliance and increase the chance of recovery. The acceptability of a newly developed
metronidazole oral suspension for dogs (Eradia® 125 mg/ml suspension, Virbac, France) was compared to the
acceptability of oral tablets (Metrobactin® 500 mg, Dechra Veterinary Products, France) in medium size healthy dogs
(10-20 kg, 20 dogs), in a cross-over study. Two groups of ten dogs tested randomly the tablets or oral suspension for 5
days before switching to the other formulation, with a 2-day wash-out period between administration periods. Each
dog received 25 mg/kg of metronidazole, twice a day, according to the manufacturerâ??s instructions. Therefore, each
product was given a total of 200 times during the trial. The suspension was poured on the kibbles while the tablets
were given as such. Dogs were observed at each administration for 10 min to check if they took and consumed the
product. Product intake and consumption rates were compared using a Chi² test or Fischerâ??s exact test. Spontaneous
prehension of the product was observed significantly more often with the oral suspension than with the tablets
[162/200 times (81%) versus 102/200 times (51%) - p<0.001]. The consumption of more than 95% of product was
also observed more often with Eradia® than with Metrobactin® [162/200 (81%) versus 48/200 (24%) - p<0.001].
Therefore, the acceptability of a metronidazole treatment by dogs was better with Eradia® 125 mg/ml oral suspension
than with Metrobactin® 500 mg tablets.
Recent Publications
1. Faure L, Fournel S, Nicolas C S and Rigaut D (2018) A field clinical study to confirm the efficacy and safety of
a metronidazole-based oral suspension in dogs naturally infested by giardiasis: comparison to fenbendazole.
Intern J Appl Res Vet Med 16(2):110-11.
E-mail: christine.adam@virbac.com
Veterinary Science & Technology received 4472 citations as per Google Scholar report